Page last updated: 2024-10-23
bumetanide and Autism
bumetanide has been researched along with Autism in 20 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of bumetanide oral solution for the treatment of autism spectrum disorder (ASD) in children and adolescents was evaluated in two international, multi-center, randomized, double-blind, placebo-controlled phase III trials; one enrolled patients aged 7-17 years (SIGN 1 trial) and the other enrolled younger patients aged 2-6 years (SIGN 2)." | 9.69 | Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies. ( Albarran, C; Ben Ari, Y; Crutel, V; Fuentes, J; Georgoula, C; Lambert, E; Marret, S; Oliveira, G; Parellada, M; Pénélaud, PF; Ravel, D, 2023) |
| "With the current limited drug therapy for the core symptoms of autism spectrum disorder (ASD), we herein report a randomized, double-blind, placebo-controlled trial to investigate the efficacy, safety, and potential neural mechanism of bumetanide in children with ASD aged 3-6 years old." | 9.41 | Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. ( Dai, Y; Deng, S; Du, X; Feng, J; He, H; Ji, Y; Langley, C; Li, F; Li, WG; Liu, X; Luo, Q; Sahakian, BJ; Tang, Y; Wang, K; Yu, J; Zhang, J; Zhang, L; Zhou, X, 2021) |
| "Recent trials have indicated positive effects of bumetanide in autism spectrum disorder (ASD)." | 9.41 | Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial. ( Bruining, H; Keijzer-Veen, MG; Lilien, MR; Oranje, B; Scheepers, FE; Schulp, AJA; Sprengers, JJ; van Andel, DM; Zuithoff, NPA, 2021) |
| "Bumetanide has been reported to alter synaptic excitation-inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models." | 9.34 | Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. ( Dai, Y; Deng, S; Du, X; Feng, J; Huang, CC; Ji, Y; Li, F; Lin, CP; Luo, Q; Sahakian, BJ; Shen, C; Tang, Y; Wang, K; Xu, M; Yu, J; Zhang, L, 2020) |
| "The purpose of this study was to investigate the therapeutic effects of combined bumetanide and applied behavior analysis (ABA) treatment in children with autism." | 9.20 | A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism. ( Du, L; Jia, F; Li, H; Shan, L; Staal, WG; Wang, B; Xu, Z, 2015) |
| "Bumetanide, a drug being studied in autism spectrum disorder (ASD) may act to restore gamma-aminobutyric acid (GABA) function, which may be modulated by the immune system." | 8.12 | The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder. ( Dai, Y; He, H; Langley, C; Li, F; Li, Q; Li, WG; Luo, Q; Sahakian, BJ; Shan, H; Yao, Y; Yu, J; Zhang, L, 2022) |
| "Bumetanide, a diuretic agent, that reduces intracellular chloride-thereby reinforcing GABAergic inhibition-has been reported to improve core symptoms of autism in children." | 8.02 | Bumetanide for autism: Open-label trial in six children. ( Fernell, E; Gillberg, C; Gustafsson, P, 2021) |
| "We report that the oxytocin-mediated neuroprotective γ-aminobutyric acid (GABA) excitatory-inhibitory shift during delivery is abolished in the valproate and fragile X rodent models of autism." | 7.80 | Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. ( Ben-Ari, Y; Brouchoud, C; Burnashev, N; Chazal, G; Eftekhari, S; Ferrari, DC; Khalilov, I; Lemonnier, E; Lozovaya, N; Nardou, R; Shahrokhi, A; Tsintsadze, T; Tsintsadze, V; Tyzio, R, 2014) |
| "Sixty children with autism or Asperger syndrome (3-11 years old) received for 3 months placebo or bumetanide (1 mg daily), followed by 1-month wash out." | 6.77 | A randomised controlled trial of bumetanide in the treatment of autism in children. ( Ben-Ari, Y; Degrez, C; Grandgeorge, M; Hadjikhani, N; Josse, F; Lemonnier, E; Phelep, M; Tyzio, R, 2012) |
| "The efficacy and safety of bumetanide oral solution for the treatment of autism spectrum disorder (ASD) in children and adolescents was evaluated in two international, multi-center, randomized, double-blind, placebo-controlled phase III trials; one enrolled patients aged 7-17 years (SIGN 1 trial) and the other enrolled younger patients aged 2-6 years (SIGN 2)." | 5.69 | Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies. ( Albarran, C; Ben Ari, Y; Crutel, V; Fuentes, J; Georgoula, C; Lambert, E; Marret, S; Oliveira, G; Parellada, M; Pénélaud, PF; Ravel, D, 2023) |
| "With the current limited drug therapy for the core symptoms of autism spectrum disorder (ASD), we herein report a randomized, double-blind, placebo-controlled trial to investigate the efficacy, safety, and potential neural mechanism of bumetanide in children with ASD aged 3-6 years old." | 5.41 | Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial. ( Dai, Y; Deng, S; Du, X; Feng, J; He, H; Ji, Y; Langley, C; Li, F; Li, WG; Liu, X; Luo, Q; Sahakian, BJ; Tang, Y; Wang, K; Yu, J; Zhang, J; Zhang, L; Zhou, X, 2021) |
| "Recent trials have indicated positive effects of bumetanide in autism spectrum disorder (ASD)." | 5.41 | Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial. ( Bruining, H; Keijzer-Veen, MG; Lilien, MR; Oranje, B; Scheepers, FE; Schulp, AJA; Sprengers, JJ; van Andel, DM; Zuithoff, NPA, 2021) |
| "Bumetanide has been reported to alter synaptic excitation-inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models." | 5.34 | Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios. ( Dai, Y; Deng, S; Du, X; Feng, J; Huang, CC; Ji, Y; Li, F; Lin, CP; Luo, Q; Sahakian, BJ; Shen, C; Tang, Y; Wang, K; Xu, M; Yu, J; Zhang, L, 2020) |
| "The purpose of this study was to investigate the therapeutic effects of combined bumetanide and applied behavior analysis (ABA) treatment in children with autism." | 5.20 | A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism. ( Du, L; Jia, F; Li, H; Shan, L; Staal, WG; Wang, B; Xu, Z, 2015) |
| "Bumetanide, a drug being studied in autism spectrum disorder (ASD) may act to restore gamma-aminobutyric acid (GABA) function, which may be modulated by the immune system." | 4.12 | The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder. ( Dai, Y; He, H; Langley, C; Li, F; Li, Q; Li, WG; Luo, Q; Sahakian, BJ; Shan, H; Yao, Y; Yu, J; Zhang, L, 2022) |
| "Bumetanide, a diuretic agent, that reduces intracellular chloride-thereby reinforcing GABAergic inhibition-has been reported to improve core symptoms of autism in children." | 4.02 | Bumetanide for autism: Open-label trial in six children. ( Fernell, E; Gillberg, C; Gustafsson, P, 2021) |
| "Before we elaborate on the postulated discrepancies between our trial and previous bumetanide in autism spectrum disorder (ASD) trials, we would like to acknowledge the crucial pioneering work on the γ-aminobutyric acid (GABA) developmental sequence by Dr." | 4.02 | Dr. Sprengers et al. Reply. ( Bruining, H; Sprengers, JJ; van Andel, DM, 2021) |
| "We report that the oxytocin-mediated neuroprotective γ-aminobutyric acid (GABA) excitatory-inhibitory shift during delivery is abolished in the valproate and fragile X rodent models of autism." | 3.80 | Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. ( Ben-Ari, Y; Brouchoud, C; Burnashev, N; Chazal, G; Eftekhari, S; Ferrari, DC; Khalilov, I; Lemonnier, E; Lozovaya, N; Nardou, R; Shahrokhi, A; Tsintsadze, T; Tsintsadze, V; Tyzio, R, 2014) |
| "Sixty children with autism or Asperger syndrome (3-11 years old) received for 3 months placebo or bumetanide (1 mg daily), followed by 1-month wash out." | 2.77 | A randomised controlled trial of bumetanide in the treatment of autism in children. ( Ben-Ari, Y; Degrez, C; Grandgeorge, M; Hadjikhani, N; Josse, F; Lemonnier, E; Phelep, M; Tyzio, R, 2012) |
| " Bumetanide was administered daily (1mg daily) during a 3-month period and clinical and biological tests made." | 1.36 | The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. ( Ben-Ari, Y; Lemonnier, E, 2010) |
Research
Studies (20)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 12 (60.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ben-Ari, Y | 8 |
| Cherubini, E | 1 |
| Georgoula, C | 2 |
| Ferrin, M | 1 |
| Pietraszczyk-Kedziora, B | 1 |
| Hervas, A | 1 |
| Marret, S | 2 |
| Oliveira, G | 2 |
| Rosier, A | 1 |
| Crutel, V | 2 |
| Besse, E | 1 |
| Severo, CA | 1 |
| Ravel, D | 2 |
| Fuentes, J | 2 |
| Li, Q | 1 |
| Zhang, L | 3 |
| Shan, H | 1 |
| Yu, J | 3 |
| Dai, Y | 3 |
| He, H | 2 |
| Li, WG | 2 |
| Langley, C | 2 |
| Sahakian, BJ | 3 |
| Yao, Y | 1 |
| Luo, Q | 3 |
| Li, F | 3 |
| Zhou, X | 1 |
| Ji, Y | 2 |
| Wang, K | 2 |
| Du, X | 2 |
| Liu, X | 1 |
| Tang, Y | 2 |
| Deng, S | 2 |
| Zhang, J | 1 |
| Feng, J | 2 |
| Parellada, M | 1 |
| Albarran, C | 1 |
| Lambert, E | 1 |
| Pénélaud, PF | 1 |
| Ben Ari, Y | 1 |
| Huang, CC | 1 |
| Xu, M | 1 |
| Shen, C | 1 |
| Lin, CP | 1 |
| Sprengers, JJ | 2 |
| van Andel, DM | 2 |
| Zuithoff, NPA | 1 |
| Keijzer-Veen, MG | 1 |
| Schulp, AJA | 1 |
| Scheepers, FE | 1 |
| Lilien, MR | 1 |
| Oranje, B | 1 |
| Bruining, H | 2 |
| Vitiello, B | 1 |
| Fernell, E | 1 |
| Gustafsson, P | 1 |
| Gillberg, C | 2 |
| Lemonnier, E | 7 |
| Rabiei, H | 1 |
| Makowski, D | 1 |
| Hadjikhani, N | 4 |
| Nau, JY | 2 |
| Åsberg Johnels, J | 1 |
| Lassalle, A | 1 |
| Zürcher, NR | 2 |
| Hippolyte, L | 2 |
| Rogier, O | 1 |
| Ruest, T | 1 |
| Tyzio, R | 2 |
| Nardou, R | 1 |
| Ferrari, DC | 1 |
| Tsintsadze, T | 1 |
| Shahrokhi, A | 1 |
| Eftekhari, S | 1 |
| Khalilov, I | 1 |
| Tsintsadze, V | 1 |
| Brouchoud, C | 1 |
| Chazal, G | 1 |
| Lozovaya, N | 1 |
| Burnashev, N | 1 |
| Du, L | 1 |
| Shan, L | 1 |
| Wang, B | 1 |
| Li, H | 1 |
| Xu, Z | 1 |
| Staal, WG | 1 |
| Jia, F | 1 |
| Degrez, C | 1 |
| Phelep, M | 1 |
| Josse, F | 1 |
| Grandgeorge, M | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Efficiency of a Treatment by Bumetanide in a Population of Autistic Children[NCT01078714] | Phase 3 | 60 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
1 review available for bumetanide and Autism
| Article | Year |
|---|---|
The GABA Polarity Shift and Bumetanide Treatment: Making Sense Requires Unbiased and Undogmatic Analysis.
Topics: Animals; Autistic Disorder; Brain; Bumetanide; Chlorides; gamma-Aminobutyric Acid | 2022 |
Trials
8 trials available for bumetanide and Autism
| Article | Year |
|---|---|
A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.
Topics: Adolescent; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Double-Blind Method; Fem | 2023 |
Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Child, Preschool; gamma-Aminobutyric | 2021 |
Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies.
Topics: Adolescent; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Double-Blind Method; Hum | 2023 |
Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA/glutamate ratios.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Child, Preschool; gamma-Aminobutyric | 2020 |
Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Double-Blind Method; Humans; Membran | 2021 |
Bumetanide for autism: more eye contact, less amygdala activation.
Topics: Adolescent; Adult; Amygdala; Autistic Disorder; Bumetanide; Double-Blind Method; Emotions; Female; F | 2018 |
A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism.
Topics: Autistic Disorder; Behavior Therapy; Bumetanide; Checklist; Child; Child, Preschool; Combined Modali | 2015 |
A randomised controlled trial of bumetanide in the treatment of autism in children.
Topics: Asperger Syndrome; Autistic Disorder; Bumetanide; Child; Child, Preschool; Double-Blind Method; Fema | 2012 |
Other Studies
11 other studies available for bumetanide and Autism
| Article | Year |
|---|---|
The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Child, Preschool; Cytokines; gamma-A | 2022 |
Editorial: Targeting the Core Symptoms of Autism Spectrum Disorder With Mechanism-Based Medications.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Communication; Humans | 2021 |
Bumetanide for autism: Open-label trial in six children.
Topics: Adolescent; Autistic Disorder; Bumetanide; Child; Child, Preschool; Humans; Male; Parents; Pilot Pro | 2021 |
Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?
Topics: Autism Spectrum Disorder; Autistic Disorder; Bumetanide; Child; Humans | 2021 |
Dr. Sprengers et al. Reply.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; gamma-Aminobutyric Acid; Humans; N | 2021 |
Using bumetanide to treat autism appears promising but further clinical trials are needed to confirm this approach.
Topics: Autistic Disorder; Bumetanide; Child; Humans | 2021 |
Topics: Autistic Disorder; Bumetanide; Child; Child, Preschool; Diuretics; Humans; Treatment Outcome | 2017 |
Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study.
Topics: Adolescent; Adult; Autistic Disorder; Brain; Bumetanide; Emotions; Facial Expression; Humans; Magnet | 2015 |
Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring.
Topics: Animals; Autistic Disorder; Behavior, Animal; Bumetanide; Chlorides; Cytoprotection; Disease Models, | 2014 |
The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects.
Topics: Autistic Disorder; Bumetanide; Child; Child, Preschool; Chlorides; Diuretics; Female; Follow-Up Stud | 2010 |
[To dare trying a diuretic in autism treatment].
Topics: Asperger Syndrome; Autistic Disorder; Bumetanide; Child; Child, Preschool; Diuretics; Drug Repositio | 2012 |